使用度普利尤单抗和JAK抑制剂治疗痒疹型大疱性表皮松解症瘙痒的真实世界经验。
Real-world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa.
作者信息
Hou Ping-Chen, Aala Wilson, Tu Wei-Ting, McGrath John A, Hsu Chao-Kai
机构信息
Department of Dermatology National Cheng Kung University Hospital College of Medicine National Cheng Kung University Tainan Taiwan.
Institute of Clinical Medicine College of Medicine National Cheng Kung University Tainan Taiwan.
出版信息
Skin Health Dis. 2024 Aug 19;4(5):e445. doi: 10.1002/ski2.445. eCollection 2024 Oct.
Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.
痒疹性大疱性表皮松解症（EBP）是一种与严重瘙痒相关的营养不良型大疱性表皮松解症，具有偏向性的Th2炎症。我们的研究表明，在治疗EBP方面，与度普利尤单抗相比，JAK抑制剂可能具有更高的疗效。此外，JAK抑制剂可下调皮损皮肤中的JAK-STAT信号传导和Th1/2细胞分化，而在外周血中则无此作用。
Zotero 插件